Lilly Stock Jumps After Phase 3 Weight-Drug Readout
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
A stock index measures the performance of a defined group of stocks, reflecting overall market or segment trends for comparison.
20,961 articlesLilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
Nvidia stock pulled back from late-May highs, creating a potential dip-buy opportunity as AI demand shows no clear sl...
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
With SPY's yield hovering near 1% and valuations high, investors are turning to covered calls to generate cash flow. ...
Rambus rides AI infrastructure tailwinds but keeps a neutral stance as investors weigh valuation against accelerating...
Adobe has pulled back about 40% from its peak, but new AI-driven products and expanding ARR are reinvigorating the bu...
Two tech giants define growth storytelling in 2026: one leads cloud security, the other powers AI infrastructure. Thi...
PSEG's steady, regulated core supports its payout, but 2025 earnings hinge on rate cases, fuel costs, and clean energ...
As electric-vehicle charging scales up, ChargePoint's 2026 earnings outlook becomes a key signal for investors. This ...
Geopolitics can tip energy costs, and that ripple reaches AI markets. Learn how the Iran conflict briefly sent oil pa...
Centuri Holdings ends 2025 with a booming backlog and falling debt, yet investors face a high bar to justify lofty va...
As AI demand reshapes chips, Intel and Arm sit at opposite ends of the risk spectrum. This analysis weighs which AI-e...